Ovid Therapeutics

About:

Ovid Therapeutic's purpose is to solve intractable medical problems.

Website: http://www.ovidrx.com/

Twitter/X: OvidRx

Top Investors: Fidelity, Cormorant Asset Management, Redmile Group, Jennison Associates, Tekla Capital Management

Description:

Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based on key insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe.

Total Funding Amount:

$184M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2014-01-01

Contact Email:

info(AT)ovidrx.com

Founders:

Matthew J. During

Number of Employees:

11-50

Last Funding Date:

2019-10-04

IPO Status:

Public

Industries:

© 2025 bioDAO.ai